For research use only. Not for therapeutic Use.
Xaliproden (codenamed SR57746) is a drug which acts as a 5HT1A agonist. It has neurotrophic and neuroprotective effects in vitro, and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis and Alzheimer/’s disease. Xaliproden remains under investigation for treatment of chemotherapy-induced peripheral neuropathy due to it not reaching required significance levels.
| Catalog Number | R034296 |
| CAS Number | 90494-79-4 |
| Synonyms | 1-[2-(2-Naphthyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1,2,3,6-Tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine |
| Molecular Formula | C24H23ClF3N |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Storage | -20°C |
| IUPAC Name | 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine;hydrochloride |
| InChI | InChI=1S/C24H22F3N.ClH/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18;/h1-9,11,16-17H,10,12-15H2;1H |
| InChIKey | WVHBEIJGAINUBW-UHFFFAOYSA-N |
| SMILES | C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3.Cl |
| Reference | </br>1:5-HT1A receptor agonists, xaliproden and tandospirone, inhibit the increase in the number of cutaneous mast cells involved in the exacerbation of mechanical allodynia in oxaliplatin-treated mice. Andoh T, Sakamoto A, Kuraishi Y.J Pharmacol Sci. 2016 Aug;131(4):284-7. doi: 10.1016/j.jphs.2016.07.008. Epub 2016 Aug 4. PMID: 27562704 Free Article</br>2:Effects of xaliproden, a 5-HT₁A agonist, on mechanical allodynia caused by chemotherapeutic agents in mice. Andoh T, Sakamoto A, Kuraishi Y.Eur J Pharmacol. 2013 Dec 5;721(1-3):231-6. doi: 10.1016/j.ejphar.2013.09.030. Epub 2013 Sep 23. PMID: 24070812 </br>3:SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases. Porzner M, Müller T, Seufferlein T.Expert Opin Investig Drugs. 2009 Nov;18(11):1765-72. doi: 10.1517/13543780903329089. Review. PMID: 19814656 </br>4:5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A.Br J Pharmacol. 2009 Sep;158(1):232-42. doi: 10.1111/j.1476-5381.2009.00249.x. Epub 2009 Jun 5. PMID: 19508400 Free PMC Article</br>5:What we have learned from the Xaliproden Sanofi-aventis trials. Douillet P, Orgogozo JM.J Nutr Health Aging. 2009 Apr;13(4):365-6. No abstract available. PMID: 19300882 </br>6:Xaliproden lessens oxaliplatin-mediated neuropathy. Susman E.Lancet Oncol. 2006 Apr;7(4):288. No abstract available. PMID: 16598880 </br>7:Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis. Labie C, Canolle B, Chatelin S, Lafon C, Fournier J.Curr Alzheimer Res. 2006 Feb;3(1):35-6. Review. No abstract available. PMID: 16472201 </br>8:Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells. Appert-Collin A, Duong FH, Passilly DeGrace P, Bennasroune A, Poindron P, Warter JM, Gies JP.Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):233-44. PMID: 15888246 </br>9:MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden. Appert-Collin A, Duong FH, Passilly Degrace P, Warter JM, Poindron P, Gies JP.Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):21-31. PMID: 15698508 </br>10:Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, Lacomblez L, Leigh PN, Robberecht W.Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):107-17. PMID: 15204012 |
